Expression of G-protein Coupled Receptor 120 Receptor in Adipose Tissue of German Diabetes Center Cohort Subjects
NCT03285750 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2023-06-15
Summary
G-protein coupled receptor 120 (GPR120) is a G-protein-coupled receptor whose endogenous ligands have been identified as long-chain fatty acids. Recently, it has been shown that GPR120 expression in human adipose tissue is higher in obese than in lean individuals. Interestingly, a GPR120 deficient mouse model presents an unfavorable phenotype when fed a high-fat diet with obesity, glucose intolerance and fatty liver, characteristics also found in type 2 diabetes (T2D).
Moreover, in obese subjects, a single nucleotide polymorphism (R270H) has been identified that inhibits GPR120 signaling activity.
The investigators now want to investigate if GPR120 expression in adipose tissue may be altered in patients with T2D compared to non-diabetic subjects and might contribute to diabetes-associated metabolic changes. Additionally, the investigators want to assess the frequency of the R270H mutant in T2D.
Conditions
Sponsors & Collaborators
-
German Diabetes Center
lead OTHER
Principal Investigators
-
Michael Roden, Prof., MD · German Diabetes Center
Eligibility
- Min Age
- 20 Years
- Max Age
- 69 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-08-31
- Primary Completion
- 2017-09-30
- Completion
- 2017-09-30
Countries
- Germany
Study Locations
More Related Trials
-
The Acute Effects of Low-dose TNF-α on Glucose Metabolism and β-cell Function in Humans
NCT01953393 ·Status: COMPLETED ·Phase: NA
-
Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
NCT00738023 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia
NCT00418288 ·Status: COMPLETED ·Phase: NA
-
Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic Steatosis
NCT04907721 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
NCT01507597 ·Status: COMPLETED ·Phase: NA
-
Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients
NCT02655770 ·Status: COMPLETED ·Phase: PHASE4
-
Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia
NCT02337660 ·Status: COMPLETED ·Phase: NA
-
Adiponectin in Obese Women With T2DN and Effects by RAS Blocker
NCT00561704 ·Status: COMPLETED ·Phase: NA
-
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists
NCT06818292 ·Status: COMPLETED ·Phase: NA
-
Glucolipotoxicity and Type 2 Diabetes
NCT01375270 ·Status: COMPLETED ·Phase: NA
-
Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1
NCT01347801 ·Status: COMPLETED ·Phase: NA
-
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
NCT02833415 ·Status: COMPLETED ·Phase: PHASE4
-
The Effects of Glucagon on Hepatic Metabolism
NCT05500586 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect
NCT00784745 ·Status: COMPLETED ·Phase: NA
-
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)
NCT06774807 ·Status: COMPLETED ·Phase: NA
-
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
NCT05093517 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)
NCT00862589 ·Status: COMPLETED ·Phase: NA
-
Central Insulin Sensitivity in Individuals With Type 2 Diabetes (T2D) and at Risk for Developing T2D
NCT05856877 ·Status: RECRUITING ·Phase: NA
-
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
NCT00212290 ·Status: COMPLETED ·Phase: PHASE4
-
Peripheral Metabolic Effects of Ghrelin
NCT00771940 ·Status: COMPLETED ·Phase: PHASE1
-
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
NCT01234649 ·Status: COMPLETED ·Phase: PHASE3
-
GLP1R Polymorphisms and Response to GLP1
NCT00588380 ·Status: COMPLETED ·Phase: NA
-
Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls
NCT01674972 ·Status: COMPLETED
-
Liraglutide and Heart Failure in Type 2 Diabetes
NCT01425580 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity
NCT06845033 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA